Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

108.44 -0.65 (-0.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,591,826
Open 109.11
Bid (Size) 107.52 (1)
Ask (Size) 108.34 (2)
Prev. Close 109.09
Today's Range 107.23 - 109.45
52wk Range 62.07 - 119.96
Shares Outstanding 1,253,809,440
Dividend Yield 2.91%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) – A Potentially Undervalued Biopharmaceutical Stock
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability, a solid dividend, and reasonable growth potential, making it a candidate for value investors. 
Via Chartmill

Performance

YTD
+18.0%
+18.0%
1 Month
+2.0%
+2.0%
3 Month
-2.3%
-2.3%
6 Month
+19.8%
+19.8%
1 Year
+69.6%
+69.6%

More News

Read More
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
What Analysts Are Saying About Gilead Sciences Stock
Via Benzinga
What's going on in today's session: S&P500 movers
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
From Gilead Sciences, Inc.
Via Business Wire
Is the Market Bullish or Bearish on Gilead Sciences?
Via Benzinga
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
Via StockStory
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Top S&P500 movers in Monday's pre-market session
Via Chartmill
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation
Via Benzinga
Topics Economy World Trade
Exposures Interest Rates Tariff
GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss
Via StockStory
Exposures COVID-19 Product Safety
2 High-Yield Dividend Stocks to Buy in May and Hold Forever
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Market Monitor May 9 (Boeing, MicroStrategy UP - Match Group DOWN)
Via Chartmill
Topics Economy
Exposures Interest Rates
3 Value Stocks with Mounting Challenges
Via StockStory
Exposures COVID-19
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
From Gilead Sciences, Inc.
Via Business Wire
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Via Benzinga
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
From Gilead Sciences, Inc.
Via Business Wire
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN)
Via Chartmill
GILEAD SCIENCES INC (NASDAQ:GILD) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
1 Profitable Stock on Our Watchlist and 2 to Turn Down
Via StockStory
Exposures COVID-19
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
Via MarketBeat
Topics Economy World Trade
Exposures COVID-19 Supply Chain Tariff
Gilead Sciences Inc (NASDAQ:[GILD](https://www.chartmill.com/stock/quote/GILD)): A Dividend Stock Worth Considering
Via Chartmill
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
Via The Motley Fool

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 108.44
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 05/28/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 135.96B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 136B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.